Skip to search formSkip to main contentSkip to account menu

fulranumab

A fully human monoclonal antibody directed against nerve growth factor (NGF) with potential analgesic activity. Upon administration, fulranumab binds… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
To evaluate the long‐term safety and efficacy of fulranumab in patients with knee or hip pain caused by moderate‐to‐severe… 
Review
2016
Review
2016
There continues to be an unmet need for safe and effective pain medications. Opioids and nonsteroidal anti-inflammatory drugs… 
Review
2016
Review
2016
ABSTRACT The number of novel antibody therapeutics that received first marketing approvals in 2015 met expectations, with 6… 
2016
2016
The efficacy and safety of monotherapy with fulranumab, a monoclonal antibody that neutralises human nerve growth factor (NGF… 
Review
2014
Review
2014
It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no… 
2014
2014
Objective: To assess efficacy and safety of fulranumab, a fully human monoclonal antibody against nerve growth factor, in… 
2014
2014
Fulranumab, a human IgG2 monoclonal antibody that neutralizes nerve growth factor (NGF), is currently in development for the…